RGEN Repligen Corp stock chart & analysis
Conviction 56HealthcareScan · Fri, Nov 6, 2026Repligen Corp (RGEN) closed at $173.49 (+2.97%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 47, RS Rating 85, -12.7% from its 52-week high, +5.9% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
RGEN technical analysis
Trend
RGEN's moving averages are mixed — no clean uptrend or downtrend. It closed 2.1% below the 50-day ($177.35) and 19.7% above the 200-day ($145.00). ADX(14) at 14 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 47, in the bearish half of its range. MACD crossed below its signal line 4 sessions ago. Its RS Rating of 85 puts its weighted 12-month performance ahead of about 85% of the US market.
Volume and volatility
Volume on the latest session ran 0.5× its 20-day average. It trades about $233.5M a day on average. ATR(14) is $9.26, 5.3% of price — its typical daily range. Bollinger Bands are in a squeeze (5 sessions) — volatility is compressed. Chaikin Money Flow (0.10) shows accumulation.
Key levels
The chart pattern's support is $161.16 and its resistance $196.62. The 52-week range is $100.99 to $198.87; price is 12.7% below the high and 71.8% above the low. The VWAP anchored at the 52-week high is $178.31, above price.
Performance
RGEN returned -1.9% (1 week), +5.9% (1 month), +6.4% (3 months), +40.6% (6 months), +19.0% (1 year), +5.9% (year to date).
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Biological Products, (No Diagnostic Substances) · Listed 1986 · 2,000 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upAug 311 scan
- Broke outSep 21 – Sep 233 scans
Congress activity
Disclosed STOCK Act trades in RGEN · 6 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Lisa McClain house · MI · traded 2025-10-30 | Sell | $1K–$15K | 2025-10-30 | 2025-11-01 | |
Lisa McClain house · MI · traded 2025-10-31 | Sell | $1K–$15K | 2025-10-31 | 2025-11-01 | |
Lisa McClain house · R · MI · traded 2025-06-17 | Sell | $1K–$15K | 2025-06-17 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-07-22 | Buy | $1K–$15K | 2025-07-22 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-11 | Buy | $1K–$15K | 2025-06-11 | 2025-08-13 | |
 Jefferson Shreve house · R · IN · traded 2025-04-07 | Sell | $15K–$50K | 2025-04-07 | 2025-05-08 |
Insider activity
SEC Form 4 transactions in RGEN · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Loeillot Olivier Chief Executive Officer · Common Stock · 2026-10-02 | Tax | 1.25K | $227K | 2026-10-02 | 2026-10-05 |
Hughes Violetta CHIEF ACCOUNTING OFFICER · Common Stock · 2026-09-01 | Tax | 277 | $47K | 2026-09-01 | 2026-09-02 |
Hughes Violetta CHIEF ACCOUNTING OFFICER · Common Stock · 2026-03-05 | Grant | 2.47K | — | 2026-03-05 | 2026-09-02 |
Loeillot Olivier Chief Executive Officer · Common Stock · 2026-08-20 | Sell | 5.43K | $977K | 2026-08-20 | 2026-08-21 |
Loeillot Olivier Chief Executive Officer · Stock Option (Right to Buy) · 2026-08-20 | Exercise | 5.43K | — | 2026-08-20 | 2026-08-21 |
Loeillot Olivier Chief Executive Officer · Common Stock · 2026-08-20 | Exercise | 5.43K | $769K | 2026-08-20 | 2026-08-21 |
Garland Jason K CFO · Common Stock · 2026-07-16 | Sell | 530 | $80K | 2026-07-16 | 2026-07-17 |
BARTHELEMY NICOLAS Director · Common Stock · 2026-05-14 | Grant | 995 | $0 | 2026-05-14 | 2026-05-18 |
Pax Margaret Director · Stock Option (Right to Buy) · 2026-05-14 | Grant | 2.24K | $0 | 2026-05-14 | 2026-05-18 |
BARTHELEMY NICOLAS Director · Stock Option (Right to Buy) · 2026-05-14 | Grant | 2.24K | $0 | 2026-05-14 | 2026-05-18 |
SEC filings
EDGAR filings in RGEN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.